Prof. Markus Peck-Radosavljevic, MD MBA
Professor Markus Peck-Radosavljevic is Professor of Medicine and Chairman at the Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology at Klinikum Klagenfurt in Klagenfurt, Austria. Prof. Peck is a graduate of the Medical University of Graz Medical School, did his research training Medical University of Graz, University of Alberta in Edmonton Canada, Baylor College of Medicine in Houston Texas, and completed his clinical training in Internal Medicine, Gastroenterology/Hepatology, Infectious Diseases, and Intensive Care Medicine at the Medical University of Vienna, Austria. He began his research in liver disease in the field of portal hypertension and he has been running a translational lab testing novel approaches to the treatment of portal hypertension and HCC for many years, while working at the Medical University of Vienna. He has been actively involved in the management of post-OLT hepatitis C and has been running clinical trials in HCV-infection in hemodialysis patients and HIV-HCV coinfection. Professor Peck has served as Vice-secretary of EASL from 2011 to 2013 and as Secretary General of EASL from April 2013 to April 2015. He also served as the Secretary General of the Austrian Association for Internal Medicine from 2006-2014. He is member of the UEG Council since 2015 and Chair of the United European Gastroenterology (UEG) Public Affairs Committee (PAC), which he took over in 2018. Over many years until the end of 2015, Professor Peck has been leading the Portal Hypertension, the HIV-HCV-Coinfection, and the Hepatocellular Carcinoma (HCC) Study Groups at the Medical University of Vienna, Austria, where he has been conducting a number of clinical trials in these indications as well as on new antivirals in HCV-infection in special indications. Since January 2016, he has taken over as Chair of Internal Medicine and Gastroenterology in Klagenfurt, which also includes the Endocrinology, the Rheumatology, the Nephrology (including Hemodialysis) and the Emergency Medicine service. He has set up a new Clinical trials study unit there and is running a broad range of clinical trials in various different indications, including HCC, NASH, and Hepatitis C.